Skip to Content
Merck
All Photos(3)

Key Documents

O5015

Sigma-Aldrich

Oxybutynin chloride

meets EP, USP testing specifications

Synonym(s):

α-Phenylcyclohexaneglycolic acid 4-(diethylamino)-2-butynyl ester hydrochloride

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C22H31NO3 · HCl
CAS Number:
Molecular Weight:
393.95
EC Number:
MDL number:
UNSPSC Code:
12161900
PubChem Substance ID:
NACRES:
NA.21

Agency

USP/NF
meets EP testing specifications
meets USP testing specifications

Quality Level

form

solid

application(s)

pharmaceutical (small molecule)

storage temp.

room temp

SMILES string

Cl.CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2

InChI

1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H

InChI key

SWIJYDAEGSIQPZ-UHFFFAOYSA-N

Gene Information

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Muscarinic acetylcholine receptor antagonist; inhibits proliferation of bladder smooth muscle cells, perhaps by downregulation of growth promoting genes.

related product

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

K-S Lee et al.
International journal of clinical practice, 66(7), 663-670 (2012-06-16)
Standardised traditional outcome measures may fail to address factors that are important to patients and address irrelevant factors. Aim of this study was to assess patient-reported goals and goal achievement (GA) in the antimuscarinic treatment for overactive bladder (OAB) patients.
Lorne E Aaron et al.
Current medical research and opinion, 28(8), 1369-1379 (2012-07-10)
Evaluate patient and physician satisfaction with a novel formulation of a once-daily controlled-release (CR) oxybutynin (Uromax*) 15-mg tablet as both the initial and maintenance dose in elderly and non-elderly patients with overactive bladder (OAB). Patients not on anticholinergic treatment for
Michael H Johnson et al.
The Journal of urology, 189(4), 1268-1274 (2012-11-06)
Intravesical bacillus Calmette-Guérin is used to decrease recurrence rates of nonmuscle invasive urothelial carcinoma. Irritative urinary symptoms are a common side effect of treatment and frequently limit treatment tolerance. While anticholinergic medications may be used for symptom prophylaxis, to our
Daniele Zama et al.
Pediatric transplantation, 17(1), 86-91 (2012-12-13)
HC is a possible cause of morbidity and extended hospitalization after HSCT. Recent studies have reported the efficiency of HOT in adult patients who underwent allogeneic HSCT, but data in children are scarce. We report our single center experience with
Jessica T Casey et al.
The Journal of urology, 188(4 Suppl), 1516-1520 (2012-08-23)
Abnormal bladder function following posterior urethral valve ablation can lead to deleterious effects on renal function and urinary continence. We performed a pilot study to determine if bladder dysfunction could be ameliorated by the early administration of oxybutynin. We enrolled

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service